Tongxinshu capsules in the treatment of stable angina pectoris due to qi deficiency and blood stasis in coronary heart disease: A multicenter, randomized, double-blind, placebo-controlled trial

医学 安慰剂 心绞痛 血瘀 随机对照试验 内科学 不利影响 生活质量(医疗保健) 中医药 多中心试验 安慰剂对照研究 临床试验 双盲 外科 多中心研究 心肌梗塞 病理 替代医学 护理部
作者
Ziyi Sun,Dongsheng Zhong,Jinju Zhang,Qingqing Wang,Rongcheng Li,Tianhui Yuan,Xiaohua Dai,Jinlong Duan,Kuiwu Yao
出处
期刊:Journal of Ethnopharmacology [Elsevier BV]
卷期号:343: 119437-119437 被引量:5
标识
DOI:10.1016/j.jep.2025.119437
摘要

OBJECTIVE: To evaluate the efficacy and safety of Tongxinshu (TXS) capsules as an adjunct treatment for stable angina pectoris (SA) with Qi deficiency and blood stasis. METHODS: From September 2020 to January 2024, a multicenter, randomized, double-blind, placebo-controlled trial was conducted in three hospitals in China. A total of 120 patients with Qi deficiency and blood stasis-type SA were randomly assigned to the TXS capsule group or the placebo group (1:1). All patients received standardized Western medication and either TXS capsules or placebo capsules, administered as two capsules three times daily for eight weeks. The primary outcome measure was the angina stability score on the Seattle Angina Questionnaire (SAQ). Secondary outcome measures included other SAQ dimensions, traditional Chinese medicine (TCM) syndrome scores, quality of life assessed by the Minnesota Living with Heart Failure Questionnaire (MLHFQ), echocardiography, serum IL-6, lipid profile, and electrocardiogram changes. SAQ and TCM syndrome scores were measured at weeks 0, 4, and 8, with generalized estimating equations used for comparisons between groups at each time point. Other indices were collected at weeks 0 and 8. Adverse events (AEs) were meticulously recorded throughout the trial. RESULTS: A total of 114 patients completed the trial, with 58 in the TXS capsule group and 56 in the placebo group. Over time, both groups exhibited significant improvements in angina stability (P < 0.05), with the TXS group showing more pronounced improvements at weeks 4 and 8 compared to the placebo group (P < 0.05). Compared to baseline, both groups showed significant improvements in other SAQ dimensions, TCM syndrome scores, and MLHFQ scores (P < 0.05) after 8 weeks of treatment. Between-group comparisons revealed that the TXS group had superior improvements in physical limitation, treatment satisfaction, and TCM syndrome scores at weeks 4 and 8 (P < 0.05). Angina frequency showed significant improvement only at week 4 (P < 0.05). There was no significant difference in disease perception between the groups (P > 0.05). At week 8, the TXS group demonstrated greater improvements in MLHFQ physical domain, emotional domain, and total scores compared to the placebo group (P < 0.05). No significant differences were found between the groups in other domains (P > 0.05). Additionally, compared to baseline, the placebo group showed reductions in IL-6 and LVFS after treatment (P < 0.05). No significant differences were observed between the groups in routine blood and urine tests, electrolytes, liver and kidney functions, and electrocardiograms post-treatment (P > 0.05). Three AEs were reported in the placebo group, while no AEs occurred in the TXS group, with no statistical difference between groups (P > 0.05). CONCLUSION: The addition of TXS capsules to conventional Western medication significantly improves the severity and frequency of angina attacks, clinical symptoms, and quality of life in SA patients, with good safety (Registration number: ChiCTR2000039731).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
香蕉觅云的应助被Code_king采纳,获得10
刚刚
赘婿的应助被Code_king采纳,获得10
刚刚
小马甲的应助被Code_king采纳,获得10
1秒前
1秒前
大模型的应助被Code_king采纳,获得10
1秒前
小二郎的应助被Code_king采纳,获得10
1秒前
molihuakai的应助被Code_king采纳,获得10
1秒前
YY发布了新的文献求助10
1秒前
852的应助被Code_king采纳,获得10
1秒前
bkagyin的应助被Code_king采纳,获得10
1秒前
Hello的应助被Code_king采纳,获得10
1秒前
1秒前
ao完成签到,获得积分10
1秒前
2秒前
852的应助被winny_采纳,获得10
3秒前
停云完成签到,获得积分10
3秒前
lvy发布了新的文献求助10
3秒前
ZLQ发布了新的文献求助10
3秒前
动听千山发布了新的文献求助10
4秒前
十一完成签到,获得积分10
4秒前
袁大头发布了新的文献求助10
4秒前
Y_发布了新的文献求助10
4秒前
4秒前
李爱国的应助被缙云山2020采纳,获得10
4秒前
5秒前
Xumoc完成签到,获得积分10
5秒前
5秒前
猪皮恶人发布了新的文献求助10
5秒前
5秒前
陈饱饱完成签到,获得积分10
6秒前
6秒前
6秒前
思源的应助被add采纳,获得10
6秒前
6秒前
7秒前
7秒前
斯文败类的应助被dzx采纳,获得10
7秒前
7秒前
8秒前
renren发布了新的文献求助10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8176287
求助须知:如何正确求助?哪些是违规求助? 9567719
关于积分的说明 21794359
捐赠科研通 7771008
什么是DOI,文献DOI怎么找? 3431998
关于科研通互助平台的介绍 2556315
邀请新用户注册赠送积分活动 2477650